OVERSEA CHINESE BANKING Corp Ltd Acquires 2,847 Shares of Eli Lilly and Company $LLY

OVERSEA CHINESE BANKING Corp Ltd raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 16.1% in the third quarter, Holdings Channel.com reports. The firm owned 20,575 shares of the company’s stock after buying an additional 2,847 shares during the period. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Eli Lilly and Company were worth $15,606,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Brighton Jones LLC raised its holdings in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Seaside Wealth Management Inc. raised its position in shares of Eli Lilly and Company by 3.9% in the second quarter. Seaside Wealth Management Inc. now owns 691 shares of the company’s stock valued at $539,000 after purchasing an additional 26 shares during the period. Sapient Capital LLC boosted its holdings in Eli Lilly and Company by 0.8% in the 2nd quarter. Sapient Capital LLC now owns 1,218,487 shares of the company’s stock worth $949,847,000 after buying an additional 9,903 shares during the period. Finally, Sunpointe LLC boosted its holdings in Eli Lilly and Company by 14.9% in the 2nd quarter. Sunpointe LLC now owns 1,183 shares of the company’s stock worth $922,000 after buying an additional 153 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on LLY shares. Zacks Research raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 1st. Daiwa Capital Markets set a $1,230.00 price objective on Eli Lilly and Company and gave the stock a “buy” rating in a report on Tuesday, December 16th. HSBC restated a “hold” rating and issued a $1,070.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Daiwa America raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 16th. Finally, Wolfe Research boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Five analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $1,174.70.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan coverage highlights continued GLP‑1 sales strength and pipeline-driven momentum entering 2026, reinforcing expectations for revenue growth from obesity and next‑generation incretin candidates. JPM26: Eli Lilly enters 2026 with strong momentum given pipeline innovation
• Positive Sentiment: JPMorgan also highlights commercial and governmental access efforts for Lilly’s obesity drugs — implying management focus on scaling reimbursement and market penetration, which supports longer‑term sales trajectory. JPM26: Eli Lilly’s obesity drugs target commercial and governmental access
• Positive Sentiment: Analysts continue to back LLY: Jefferies reaffirmed a Buy with a $1,300 target and BMO kept a Buy — signals that sell‑side expectations remain bullish despite near‑term noise. Where is Eli Lilly and Company (LLY) Headed According to Analysts?
• Positive Sentiment: CEO David Ricks reiterated ambition and portfolio outlook (including obesity launches) in a recent interview, which supports confidence in execution and the company’s sizable market opportunity. Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook
• Neutral Sentiment: Lilly’s AI collaboration mentions (e.g., with NVIDIA) position the company on the technological edge of drug discovery — positive structurally but not an immediate revenue driver. JPM: NVIDIA Launches AI Collaborations with Eli Lilly, Thermo Fisher
• Negative Sentiment: FDA reportedly delayed its decision on Lilly’s oral obesity candidate orforglipron (a priority‑voucher recipient), creating uncertainty about near‑term market timing and catalyzing a negative trader reaction. FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report
• Negative Sentiment: A compounding pharmacy has filed suit alleging coordinated conduct by Lilly and Novo Nordisk around GLP‑1 dominance; legal/legal‑risk headlines add regulatory and reputational uncertainty for the GLP‑1 franchise. Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,032.51 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The stock has a market cap of $976.11 billion, a P/E ratio of 50.51, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. The firm’s fifty day moving average price is $1,049.04 and its 200-day moving average price is $868.38.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the firm earned $1.18 earnings per share. The firm’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.